# A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease

> **NCT06602258** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Eisai Inc.** · enrollment: 105 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** E2814
- **DRUG:** Lecanemab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06602258
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-30
- **Primary completion:** 2026-12-03
- **Final completion:** 2027-08-18
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06602258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06602258, "A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06602258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*